Email Alert RSS English | 中文
Advanced Search
ZHANG Yi-zhuo, CHEN Yi-jian. Research updates on diabetic foot infection[J]. Chin J Clin Med, 2023, 30(1): 18-23. DOI: 10.12025/j.issn.1008-6358.2023.20230085
Citation: ZHANG Yi-zhuo, CHEN Yi-jian. Research updates on diabetic foot infection[J]. Chin J Clin Med, 2023, 30(1): 18-23. DOI: 10.12025/j.issn.1008-6358.2023.20230085
shu

Research updates on diabetic foot infection

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China

Funds: Supported by the National Key Clinical Specialty Construction Program of China in 2021—Construction of the multidisciplinary team for the diagnosis and treatment of diabetic foot in Huashan Hospital
More Information
  • Received Date: January 29, 2023
  • Accepted Date: February 12, 2023
    Graphical Abstract
    • Abstract

  • Diabetic foot infection (DFI) is one of the common complications of diabetes mellitus, which can lead to amputation or even death. Recently, the prevalence of multi-drug resistant bacteria has posed a serious challenge to the diagnosis and treatment of DFI in the clinical context. Based on the epidemiology of DFI and individualized pathogenic analysis, timely and rational administration of effective antibiotics is a vital measure to improve patients' prognosis. This review focuses on research updates in such aspects of DFI, with the purpose of providing a reference for clinical work.

    • FullText(HTML)
    • References (41)
  • [1]
    GBD DISEASES AND INJURIES COLLABORATORS. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222. DOI: 10.1016/S0140-6736(20)30925-9
    [2]
    LAZZARINI P A, CRAMB S M, GOLLEDGE J, et al. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century[J]. Diabetologia, 2023, 66(2): 267-287. DOI: 10.1007/s00125-022-05845-9
    [3]
    VAN NETTEN J J, BUS S A, APELQVIST J, et al. Definitions and criteria for diabetic foot disease[J]. Diabetes Metab Res Rev, 2020, 36(Suppl 1): e3268.
    [4]
    LIPSKY B A, BERENDT A R, CORNIA P B, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections[J]. Clin Infect Dis, 2012, 54(12): e132-e173. DOI: 10.1093/cid/cis346
    [5]
    LIPSKY B A, ARAGÓN-SÁNCHEZ J, DIGGLE M, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes[J]. Diabetes Metab Res Rev, 2016, 32(Suppl 1): 45-74.
    [6]
    SAEEDI P, PETERSOHN I, SALPEA P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. DOI: 10.1016/j.diabres.2019.107843
    [7]
    ZHANG P Z, LU J, JING Y L, et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis[J]. Ann Med, 2017, 49(2): 106-116. DOI: 10.1080/07853890.2016.1231932
    [8]
    ARMSTRONG D G, BOULTON A J M, BUS S A. Diabetic foot ulcers and their recurrence[J]. N Engl J Med, 2017, 376(24): 2367-2375. DOI: 10.1056/NEJMra1615439
    [9]
    CHEN L H, SUN S Y, GAO Y Y, et al. Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies[J]. Diabetes Obes Metab, 2023, 25(1): 36-45. DOI: 10.1111/dom.14840
    [10]
    SAEED K, ESPOSITO S, AKRAM A, et al. Hot topics in diabetic foot infection[J]. Int J Antimicrob Agents, 2020, 55(6): 105942. DOI: 10.1016/j.ijantimicag.2020.105942
    [11]
    GIURATO L, MELONI M, IZZO V, et al. Osteomyelitis in diabetic foot: a comprehensive overview[J]. World J Diabetes, 2017, 8(4): 135-142. DOI: 10.4239/wjd.v8.i4.135
    [12]
    LAVERY L A, PETERS E J, ARMSTRONG D G, et al. Risk factors for developing osteomyelitis in patients with diabetic foot wounds[J]. Diabetes Res Clin Pract, 2009, 83(3): 347-352. DOI: 10.1016/j.diabres.2008.11.030
    [13]
    ARAGÓN-SÁNCHEZ F J, CABRERA-GALVÁN J J, QUINTANA-MARRERO Y, et al. Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement[J]. Diabetologia, 2008, 51(11): 1962-1970. DOI: 10.1007/s00125-008-1131-8
    [14]
    SAEED K, ESPOSITO S, GOULD I, et al. Hot topics in necrotising skin and soft tissue infections[J]. Int J Antimicrob Agents, 2018, 52(1): 1-10. DOI: 10.1016/j.ijantimicag.2018.02.012
    [15]
    LIPSKY B A, BERENDT A R, DEERY H G, et al. Diagnosis and treatment of diabetic foot infections[J]. Clin Infect Dis, 2004, 39(7): 885-910. DOI: 10.1086/424846
    [16]
    TENTOLOURIS N, JUDE E B, SMIRNOF I, et al. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic[J]. Diabet Med, 1999, 16(9): 767-771. DOI: 10.1046/j.1464-5491.1999.00132.x
    [17]
    GE Y, MACDONALD D, HAIT H, et al. Microbiological profile of infected diabetic foot ulcers[J]. Diabet Med, 2002, 19(12): 1032-1034. DOI: 10.1046/j.1464-5491.2002.00696_1.x
    [18]
    UÇKAY I, ARAGÓN-SÁNCHEZ J, LEW D, et al. Diabetic foot infections: what have we learned in the last 30 years?[J]. Int J Infect Dis, 2015, 40: 81-91. DOI: 10.1016/j.ijid.2015.09.023
    [19]
    DU F, MA J, GONG H P, et al. Microbial infection and antibiotic susceptibility of diabetic foot ulcer in China: literature review[J]. Front Endocrinol (Lausanne), 2022, 13: 881659. DOI: 10.3389/fendo.2022.881659
    [20]
    GRIGOROPOULOU P, ELEFTHERIADOU I, JUDE E B, et al. Diabetic foot infections: an update in diagnosis and management[J]. Curr Diab Rep, 2017, 17(1): 3. DOI: 10.1007/s11892-017-0831-1
    [21]
    LAVIGNE J P, SOTTO A, DUNYACH-REMY C, et al. New molecular techniques to study the skin microbiota of diabetic foot ulcers[J]. Adv Wound Care (New Rochelle), 2015, 4(1): 38-49. DOI: 10.1089/wound.2014.0532
    [22]
    KANDEMIR O, AKBAY E, SAHIN E, et al. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms[J]. J Infect, 2007, 54(5): 439-445. DOI: 10.1016/j.jinf.2006.08.013
    [23]
    SALTOGLU N, ERGONUL O, TULEK N, et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection[J]. Int J Infect Dis, 2018, 70: 10-14. DOI: 10.1016/j.ijid.2018.02.013
    [24]
    TASCINI C, LIPSKY B A, IACOPI E, et al. KPC-producing Klebsiella pneumoniae rectal colonization is a risk factor for mortality in patients with diabetic foot infections[J]. Clin Microbiol Infect, 2015, 21(8): 790.e1-790.e3. DOI: 10.1016/j.cmi.2015.04.010
    [25]
    PEREIRA S G, MOURA J, CARVALHO E, et al. Microbiota of chronic diabetic wounds: ecology, impact, and potential for innovative treatment strategies[J]. Front Microbiol, 2017, 8: 1791. DOI: 10.3389/fmicb.2017.01791
    [26]
    MALONE M, BJARNSHOLT T, MCBAIN A J, et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data[J]. J Wound Care, 2017, 26(1): 20-25. DOI: 10.12968/jowc.2017.26.1.20
    [27]
    XIANG J L, WANG S M, HE Y, et al. Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers[J]. Diabetes Ther, 2019, 10(1): 95-105. DOI: 10.1007/s13300-018-0536-8
    [28]
    LAZZARINI P A, CREWS R T, VAN NETTEN J J, et al. Measuring plantar tissue stress in people with diabetic peripheral neuropathy: a critical concept in diabetic foot management[J]. J Diabetes Sci Technol, 2019, 13(5): 869-880. DOI: 10.1177/1932296819849092
    [29]
    张加其, 姜晓锐, 王凯, 等. 糖尿病足感染患者的病原菌类型与病例特点及预后的相关性[J]. 医药导报, 2022, 41(9): 1360-1365. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB202209019.htm

    ZHANG J Q, JIANG X R, WANG K, et al. Correlation between pathogenic bacteria types, case characteristics, and prognosis in patients with diabetic foot infection[J]. Her Med, 2022, 41(9): 1360-1365. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB202209019.htm
    [30]
    LIPSKY B A, ARMSTRONG D G, CITRON D M, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial[J]. Lancet, 2005, 366(9498): 1695-1703. DOI: 10.1016/S0140-6736(05)67694-5
    [31]
    汪复, 张婴元. 实用抗感染治疗学[M]. 3版. 北京: 人民卫生出版社, 2020.

    WANG F, ZHANG Y Y. Practical anti-infection therapeutics[M]. 3rd ed. Beijing: People's Medical Publishing House, 2020.
    [32]
    UÇKAY I, GARIANI K, PATAKY Z, et al. Diabetic foot infections: state-of-the-art[J]. Diabetes Obes Metab, 2014, 16(4): 305-316. DOI: 10.1111/dom.12190
    [33]
    中华医学会糖尿病学分会, 中华医学会感染病学分会, 中华医学会组织修复与再生分会. 中国糖尿病足防治指南(2019版)(Ⅲ)[J]. 中华糖尿病杂志, 2019, 11(4): 238-247. DOI: 10.3760/cma.j.issn.1674-5809.2019.04.004

    Chinese Diabetes Society, Chinese Society Of Infectious Diseases, Chinese Society For Tissue Repair And Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition) (Ⅲ)[J]. Chin J Diabetes Mellit, 2019, 11(4): 238-247. DOI: 10.3760/cma.j.issn.1674-5809.2019.04.004
    [34]
    袁红, 王星海, 张菁. 噁唑烷酮类抗耐药菌新药——康替唑胺[J]. 中国感染与化疗杂志, 2021, 21(6): 765-772. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202106033.htm

    YUAN H, WANG X H, ZHANG J. Contezolid: a new oxazolidinone antibacterial agent[J]. Chin J Infect Chemother, 2021, 21(6): 765-772. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202106033.htm
    [35]
    郝敏, 秦晓华. 无氟喹诺酮类抗菌新药——奈诺沙星[J]. 中国感染与化疗杂志, 2018, 18(6): 663-671. DOI: 10.16718/j.1009-7708.2018.06.020

    HAO M, QIN X H. Nemonoxacin: a novel nonfluorinated quinolone antibiotic[J]. Chin J Infect Chemother, 2018, 18(6): 663-671. DOI: 10.16718/j.1009-7708.2018.06.020
    [36]
    POOLE R M. Nemonoxacin: first global approval[J]. Drugs, 2014, 74(12): 1445-1453. DOI: 10.1007/s40265-014-0270-0
    [37]
    JABBOUR J F, SHARARA S L, KANJ S S. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections[J]. Curr Opin Infect Dis, 2020, 33(2): 146-154. DOI: 10.1097/QCO.0000000000000635
    [38]
    PETERS E J, LIPSKY B A, BERENDT A R, et al. A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot[J]. Diabetes Metab Res Rev, 2012, 28(Suppl 1): 142-162.
    [39]
    LIPSKY B A, SENNEVILLE É, ABBAS Z G, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)[J]. Diabetes Metab Res Rev, 2020, 36(Suppl 1): e3280.
    [40]
    ARIAS M, HASSAN-RESHAT S, NEWSHOLME W. Retrospective analysis of diabetic foot osteomyelitis management and outcome at a tertiary care hospital in the UK[J]. PLoS One, 2019, 14(5): e0216701. DOI: 10.1371/journal.pone.0216701
    [41]
    GARIANI K, PHAM T T, KRESSMANN B, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial[J]. Clin Infect Dis, 2021, 73(7): e1539-e1545. DOI: 10.1093/cid/ciaa1758
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (1263) PDF downloads (587) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Links

    沪ICP备16009103号-3

    沪公网安备 31010402004907号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return